Home > Boards > US Listed > Biotechs > ImmunoGen, Inc. (IMGN)

It seems like investors don't like what IMGN

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
skitahoe Member Profile
 
Followed By 78
Posts 3,923
Boards Moderated 0
Alias Born 08/14/03
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 2/14/2020 5:20:14 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2020 4:54:02 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2020 12:40:19 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/14/2020 6:38:07 AM
ImmunoGen Reports Recent Progress and 2019 Financial Results Business Wire - 2/14/2020 6:30:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/13/2020 2:59:40 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/12/2020 3:04:36 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/12/2020 7:53:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/11/2020 9:28:30 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/11/2020 9:28:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/11/2020 9:27:09 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/11/2020 9:26:34 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/11/2020 9:25:29 AM
Schedule 13g Edgar (US Regulatory) - 2/10/2020 9:11:28 AM
ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences Business Wire - 2/6/2020 4:30:00 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/5/2020 11:50:20 AM
ImmunoGen Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire - 2/3/2020 4:30:00 PM
ImmunoGen Announces Conference Call to Discuss Its 2019 Operating Results Business Wire - 1/30/2020 4:01:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/27/2020 4:13:56 PM
ImmunoGen Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares Business Wire - 1/27/2020 4:01:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/23/2020 4:07:59 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 1/23/2020 4:06:26 PM
ImmunoGen Announces Pricing of Public Offering of Common Stock Business Wire - 1/22/2020 8:44:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/22/2020 4:10:55 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 1/22/2020 4:08:19 PM
skitahoe   Monday, 09/30/19 05:15:16 PM
Re: None
Post # of 667 
It seems like investors don't like what IMGN said, even though it's essentially what they've been saying all along. A new trial will be started this year that could have IMGN853 approve by about 2022.

I'll admit, their presentation put me to sleep, so I cannot speak to every word, but I believe they've learned much from the failed trial, and the patients in the new trial will be better qualified to receive the maximum benefits. In the failed trial there are certainly a number of patients who're still alive who wouldn't have expected to be with the SOC, but that's not the acceptance criteria. It's sad, investigators can clearly see a certain group that benefits, yet the regulators can't see it being definitive enough to approve the drug with a limited label.

Gary

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist